Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes

The outcomes for patients with lower-risk myelodysplastic syndromes (LR-MDS) by the International Prognostic Scoring System (IPSS) vary widely. For more precise prognostication, this study evaluates the prognostic value of revised IPSS with the response to hypomethylating therapy (HMT). Using the Ko...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2016-10, Vol.95 (11), p.1795-1804
Main Authors: Lee, Yoo Jin, Park, Sung Woo, Lee, In Hee, Ahn, Jae Sook, Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho Jin, Lee, Won Sik, Lee, Sang Min, Joo, Young Don, Kim, Hawk, Lee, Ho Sup, Kim, Yang Soo, Cho, Yoon Young, Moon, Joon Ho, Sohn, Sang Kyun
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Azacitidine - analogs & derivatives
Azacitidine - therapeutic use
Databases, Factual
DNA Methylation - drug effects
Female
Hematology
Humans
Kaplan-Meier Estimate
Male
Medicine
Medicine & Public Health
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Oncology
Original Article
Prognosis
Retrospective Studies
Risk
Severity of Illness Index
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outcomes for patients with lower-risk myelodysplastic syndromes (LR-MDS) by the International Prognostic Scoring System (IPSS) vary widely. For more precise prognostication, this study evaluates the prognostic value of revised IPSS with the response to hypomethylating therapy (HMT). Using the Korean MDS Working Party database, treatment outcomes for 236 patients with HMT were retrospectively evaluated. The patients were then reclassified into very low/low (VL/L), intermediate (INT), and high (H) risk groups according to IPSS-R. According to the HMT response, the 3-year overall survival (OS) did not differ between the response group (37.9 ± 9.1 %) and the stable group (52.9 ± 6.6 %, p  = 0. 782). When reclassifying according to IPSS-R, 42 patients (20.8 %) were reclassified into the H risk group. Most of them did not have benefit from continued HMT and progressed to secondary failure. The median OS was 59.0 months (range, 40.0–77.9 months) for the VL/L risk group, 31 months (range, 22.7–439.3 months) for the INT risk group, and 20.0 months (range, 15.9–24.1 months) for the H risk group ( p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-016-2759-y